Montchanin Asset Management’s Charles River Laboratories CRL Stock Holding History

Montchanin Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$258K	Buy	+1,400	New	+$270K	0.25%	46

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Montchanin Asset Management's CRL Position: Q4 2024 in Review

Montchanin Asset Management opened a new position in Charles River Laboratories (CRL) in Q4 2024: 1,400 shares worth $258K. The stake represents 0.25% of the portfolio and ranks #46 among its holdings.

637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

Montchanin Asset Management held 1,400 shares of Charles River Laboratories worth $258K as of Q4 2024.
Charles River Laboratories was a new Montchanin Asset Management position in Q4 2024.
Charles River Laboratories made up 0.25% of Montchanin Asset Management's portfolio in Q4 2024, its #46 holding.
637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Montchanin Asset Management's 13F filing for Q4 2024, filed 20 Feb 2025.